SciELO - Scientific Electronic Library Online

 
vol.128 número5Terapia triple de corto tiempo con azitromicina, amoxicilina y omeprazo para la erradicación del Helicobacter pyloriMalformaciones congénitas anorrectales y sus asociaciones preferentes. Experiencia del Hospital Clínico de la Universidad de Chile. Período 1979-1999 índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Revista

Articulo

Indicadores

Links relacionados

Compartir


Revista médica de Chile

versión impresa ISSN 0034-9887

Resumen

CATAN G, Felipe et al. BICAP tumor probe in the treatment of malignant esophageal stenosis. Rev. méd. Chile [online]. 2000, vol.128, n.5, pp.513-518. ISSN 0034-9887.  http://dx.doi.org/10.4067/S0034-98872000000500009.

Background: BICAP tumor probe is a device that consists in an energy source and olives that deliver bipolar electricity. It can be used for the fulguration of esophageal tumors after endoscopic dilatation. Aim: To report the experience in the treatment of malignant esophageal stenoses using the BICAP tumor probe. Patients and methods: Patients with advanced esophageal tumors in aphagia, that were not candidates for palliative surgery were included in this study. After endoscopic dilatation, the tumor was fulgurated with the BICAP tumor probe. Results: Twenty one patients (nine male, aged 43 to 91 years old) were treated with the device. A mean of 1.3 sessions with BICAP were necessary to obtain tumor permeabilization, which was obtained in all patients. One patient died of pneumonia 15 days after the procedure. All other patients were ingesting liquid or semisolid diets after two months of follow up. Mean survival after the procedure was 3.8 months. Conclusions: Electrical fulguration of esophageal tumors is a valid therapeutic alternative in aphagic patients. (Rev Méd Chile 2000; 128: 513-8)

Palabras clave : Esophagoscopy; Esophageal neoplasms; Esophageal stenosis.

        · texto en Español

 

Creative Commons License Todo el contenido de esta revista, excepto dónde está identificado, está bajo una Licencia Creative Commons